FDA
-
-
-
-
-
-
-
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
-
-
-
-
-
-
-
Neurogene doses patients in registrational trial for Rett syndrome therapy
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Neurogene (NGNE)
-
-
-
-
-
-
-
FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
-
-
-
-
-
-
-
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
-
-
-
-
-
-
-
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on Neurogene (NGNE)
-
329,910 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

